激素替代治疗与女性肺癌关系的研究现况分析  

Research status about female lung cancer and hormone replacement therapy

作　　者：赵爽爽[1] 许青[1] 

机构地区：[1]上海市第十人民医院肿瘤科,同济大学医学院,上海200072

出　　处：《现代肿瘤医学》2016年第10期1655-1659,共5页Journal of Modern Oncology

基　　金：上海市卫生系统先进适宜技术推广项目(编号:03.02.14.006)

摘　　要：肺癌是全球最常见的恶性肿瘤之一,在肿瘤致死原因中居第一位。女性激素替代治疗应用于卵巢功能衰退者以预防疾病、缓解症状。通过了解激素替代治疗应用现况及其与女性肺癌发生风险的研究发现,激素替代治疗可能增加、不增加甚至降低肺癌发生风险。近年来随着个体化给予低剂量的雌和(或)孕激素及新型激素的应用,使激素替代治疗更倾向于不增加肺癌发生风险。目前认为激素替代治疗不构成女性肺癌风险,在适宜人群中应用安全性高的激素,使适龄妇女在低风险的情况下获得最大收益。Lung cancer is one of the most common malignancy and the first most common causes of cancer - related death worldwide. Female hormone replacement therapy is applied to patients with ovarian function recession in order to prevent disease or relieve symptoms. By understanding the current status of hormone replacement therapy and the relationship between hormone replacement therapy and risk of the occurrence of lung cancer in women,we found that hormone replacement therapy may increase,do not increase, or even reduce the risk of lung cancer. But in recent years with individual low dose of estrogen and（or） progestin and the application of new hormone, hormone replacement therapy does not increase the incidence risk of lung cancer. At present,hormone replacement therapy does not pose a risk of lung cancer in women, the application of hormones with high safety in appropriate populations will make maximum benefit for suitable women at low risk.

关 键 词：肺癌 雌激素替代治疗 孕激素替代治疗 激素替代治疗 

分 类 号：R734.2[医药卫生—肿瘤]